A detailed history of Tema Etfs LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Tema Etfs LLC holds 14,720 shares of NTLA stock, worth $128,063. This represents 0.02% of its overall portfolio holdings.

Number of Shares
14,720
Previous 24,053 38.8%
Holding current value
$128,063
Previous $226 Million 12.68%
% of portfolio
0.02%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 24, 2025

SELL
$9.88 - $17.76 $92,210 - $165,754
-9,333 Reduced 38.8%
14,720 $254 Million
Q2 2025

Aug 13, 2025

SELL
$6.28 - $9.67 $15,599 - $24,020
-2,484 Reduced 9.36%
24,053 $226 Million
Q1 2025

May 14, 2025

SELL
$7.11 - $12.8 $864,789 - $1.56 Million
-121,630 Reduced 82.09%
26,537 $189 Million
Q4 2024

Feb 14, 2025

BUY
$11.41 - $21.09 $1.69 Million - $3.12 Million
148,167 New
148,167 $1.73 Billion

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $661M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Tema Etfs LLC Portfolio

Follow Tema Etfs LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tema Etfs LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tema Etfs LLC with notifications on news.